Annals of Oncology Advance Access originally published online on July 30, 2008
Annals of Oncology 2008 19(11):1888-1893; doi:10.1093/annonc/mdn401
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gastrointestinal tumors |
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer
1 Unità Operativa di Oncologia e Ematologia, Istituto Clinico Humanitas, Rozzano
2 Oncologia, Ospedale Gradenigo, Turin
3 Oncologia Medica, Azienda Ospedaliera S. Croce, Cuneo
4 Oncologia Medica, Istituto Oncologico, Bari
5 Servizio di Oncologia, Istituto Scientifico Universitario San Raffaele
6 Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca'Granda, Milan
7 Research & Development, AstraZeneca, Basiglio, Italy
* Correspondence to: C. Carnaghi, Via Manzoni 56, 20089 Rozzano, Milan, Italy. Tel: +39-02-82244073; Fax: +39-02-82244590; E-mail: carlo.carnaghi{at}humanitas.it
Background: Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and preclinical studies indicate that it may enhance CPT-11 cytotoxicity. This randomized phase II trial investigates the feasibility and efficacy of gefitinib and 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) in patients with metastatic colorectal cancer.
Patients and methods: Patients were randomized to FOLFIRI ± gefitinib 250 mg daily p.o. Patients randomized to FOLFIRI + gefitinib without disease progression after 6 months continued to receive gefitinib alone until disease progression.
Results: From October 2002 to September 2004, 100 patients were enrolled. Twenty-three patients (47.9%) in the FOLFIRI arm and 23 (45.1%) in the FOLFIRI + gefitinib arm experienced an objective response. The median progression-free survival and overall survival were 8.3 and 18.6 months in the FOLFIRI arm, and 8.3 and 17.1 months in the FOLFIRI + gefitinib arm, respectively. In the combination arm, grades 3–4 adverse events were experienced by 35 (67.3%) patients versus 25 patients (52.1%) in the FOLFIRI arm; 12 patients (23.1%) withdrew for an adverse event in the FOLFIRI + gefitinib arm and 5 (10.4%) in the FOLFIRI arm.
Conclusions: These data show that adding gefitinib to FOLFIRI does not improve the efficacy of FOLFIRI regimen. These disappointing results could be related to the high toxicity observed that led to significant dose reductions and delays.
Key words: colorectal cancer, EGFR, FOLFIRI, gefitinib, metastatic
Received for publication February 18, 2008. Revision received May 22, 2008. Accepted for publication May 23, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Weichert, C. Schewe, A. Lehmann, C. Sers, C. Denkert, J. Budczies, A. Stenzinger, H. Joos, O. Landt, V. Heiser, et al. KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics: Comparison of Methods and Impact of Histology J. Mol. Diagn., January 1, 2010; 12(1): 35 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. I. Block, P. B. Block, S. Reynolds Fox, J. Stouffer Birris, A. Y. Feng, M. de la Torre, D. Nathan, P. Tothy, A. K. Maki, and C. Gyllenhaal Making Circadian Cancer Therapy Practical Integr Cancer Ther, December 1, 2009; 8(4): 371 - 386. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324. [Abstract] [Full Text] [PDF]
|
|